AngioDynamics Inc. has announced the commencement of the RECOVER-AV clinical trial, marking the enrollment of the first patient. This multi-center, multi-national study aims to evaluate the AlphaVac Multipurpose Mechanical Aspiration $(MMA)$ F1885 System for the treatment of acute, intermediate-risk pulmonary embolism (PE). The trial will involve up to 20 hospital-based sites across Europe, Canada, and Hong Kong. The primary safety endpoint will assess the incidence of adverse events through 12 months, with functional and quality-of-life outcomes evaluated at 30 days and 12 months. Additional investigations, including Cardiac MRI and exercise testing, will contribute to a comprehensive assessment of long-term recovery. Results from the trial are anticipated in the future.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。